PRESS RELEASE published on 09/05/2025 at 15:00, 4 months 29 days ago Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board Onco-Innovations appoints Dr. John Mackey, expert in oncology and clinical trials, to Scientific & Clinical Advisory Board, enhancing translational research capabilities for PNKP inhibitor program Clinical Trials Oncology Onco-Innovations PNKP Inhibitor Dr. John Mackey
BRIEF published on 08/15/2025 at 15:20, 5 months 20 days ago Onco-Innovations Achieves High Warrant Exercise Rate Warrants Non-dilutive Financing Cancer Research Shareholder Confidence Capital Strategy
BRIEF published on 08/15/2025 at 15:20, 5 months 20 days ago Onco-Innovations atteint un taux d'exercice de mandat élevé Financement Non Dilutif Confiance Des Actionnaires Mandats Stratégie De Capital Recherche Sur Le Cancer
PRESS RELEASE published on 08/15/2025 at 15:15, 5 months 20 days ago Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised Onco-Innovations announces successful execution of key capital strategy with over 90% of outstanding warrants exercised at $0.60, reinforcing investor confidence and internal financing effectiveness Warrants Investor Confidence Capital Strategy Onco-Innovations Internal Financing
BRIEF published on 08/13/2025 at 23:05, 5 months 21 days ago Onco-Innovations clôture un placement privé de 400 000 $ Placement Privé Réglementation Des Valeurs Mobilières Actions Et Bons De Souscription Onco-Innovations Financement Et Développement
BRIEF published on 08/13/2025 at 23:05, 5 months 21 days ago Onco-Innovations Closes $400,000 Private Placement Private Placement Securities Regulation Shares And Warrants Onco-Innovations Funding And Development
PRESS RELEASE published on 08/13/2025 at 23:00, 5 months 21 days ago Onco-Innovations Announces Closing of Private Placement Onco-Innovations Limited announces the closing of a non-brokered private placement, raising $400,000 for general corporate purposes and cancer research. Statutory hold period applies. Not for distribution in the US Non-brokered Private Placement Cancer Research Statutory Hold Period Onco-Innovations Limited Not For Distribution
BRIEF published on 08/04/2025 at 22:10, 5 months 30 days ago Onco-Innovations ouvre la voie aux essais cliniques sur l'homme grâce à un accord clinique avancé Essai Clinique Onco-Innovations Inhibiteur De PNKP Avance Clinique Préparations Réglementaires
BRIEF published on 08/04/2025 at 22:10, 5 months 30 days ago Onco-Innovations Sets Course for Human Trials with Avance Clinical Agreement Clinical Trial Onco-Innovations PNKP Inhibitor Avance Clinical Regulatory Preparations
PRESS RELEASE published on 08/04/2025 at 22:05, 5 months 30 days ago Onco-Innovations Advances Progress Towards First-in-Human Trial with Avance Clinical Start-Up Agreement Onco-Innovations partners with Avance Clinical for regulatory and clinical documentation for their PNKP inhibitor therapy. Collaboration aims to advance cancer trials Clinical Trials Cancer Research Onco-Innovations Regulatory Support Avance Clinical
Published on 02/04/2026 at 16:15, 1 hour ago Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures
Published on 02/04/2026 at 15:45, 1 hour 30 minutes ago Patriot.Tv's Jd Rucker Explains Billie Eilish's Comments on ICE, Offers ICE Commentary as Exhibit A of Celebrity Sound Bite Politics
Published on 02/04/2026 at 15:00, 2 hours 15 minutes ago Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale
Published on 02/04/2026 at 14:30, 2 hours 45 minutes ago Core Silver Significantly Expands Copper-Molybdenum Footprint at Laverdiere Through Soil Sampling
Published on 02/04/2026 at 16:45, 29 minutes ago Agility: Global Logistics Execs Predict Volatile 2026
Published on 02/04/2026 at 16:30, 44 minutes ago EQS-Adhoc: UBS reports net profit of USD 1.2bn in 4Q25 and USD 7.8bn in FY25; increases dividend by 22% YoY; confirms 2026 targets and sets ambitions for 2028
Published on 02/04/2026 at 15:52, 1 hour 22 minutes ago Stabilus SE: Annual General Meeting approves dividend of €0.35 per share and elects Dr. Frank Heinricht to the Supervisory Board
Published on 02/04/2026 at 15:27, 1 hour 47 minutes ago EQS-Adhoc: LM Pay S.A.: Early Redemption of PLN 10M Bonds
Published on 02/04/2026 at 15:07, 2 hours 8 minutes ago Form 8.3 - The Vanguard Group, Inc.: Glencore plc
Published on 02/04/2026 at 12:50, 4 hours 24 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 02/04/2026 at 11:59, 5 hours 15 minutes ago LNA Santé : Répartition de capital et des droits de vote attachés aux actions au 31/01/2026
Published on 02/04/2026 at 11:51, 5 hours 23 minutes ago Janvier 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 02/03/2026 at 18:00, 23 hours 15 minutes ago Mint dépasse ses ambitions annoncées pour 2025 grâce à des succès commerciaux majeurs dans le BtoB
